AstraZeneca will highlight momentum of practice-changing cancer medicines across its robust pipeline at ASCO 2023
Tagrisso plenary presentation will demonstrate significantly improved overall survival for patients with early-stage resectable EGFR-mutated lung cancer. Enhertu will show potential across a broad range of advanced HER2-expressing advanced cancers. Lynparza and Imfinzi combination will demonstrate delay in progression in newly diagnosed advanced ovarian cancer without a tumour BRCA mutation.AstraZeneca advances its ambition to revolutionise cancer care with new data across its industry-leading portfolio of cancer medicines at the American Society of Clinical Oncology (ASCO) Annual Meeting,